Citigroup
OKUR

Citigroup’s OnKure Therapeutics OKUR Stock Holding History

Citigroup’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.6K Buy
12,190
+12,189
+1,218,900% +$52.3K ﹤0.01% 4940
2026
Q1 		$4 Sell
1
-3,728
-100% -$11.5K ﹤0.01% 5794
2025
Q4 		$10.8K Buy
3,729
+405
+12% +$1.21K ﹤0.01% 5033
2025
Q3 		$9.14K Buy
3,324
+3,073
+1,224% +$7.61K ﹤0.01% 5051
2025
Q2 		$600 Buy
251
+61
+32% +$160 ﹤0.01% 5434
2025
Q1 		$818 Buy
190
+88
+86% +$495 ﹤0.01% 5374
2024
Q4 		$877 Sell
102
-253
-71% -$3.83K ﹤0.01% 5604
2024
Q3 		$6.04K Sell
355
-512
-59% -$7.57K ﹤0.01% 5337
2024
Q2 		$13.1K Buy
867
+263
+44% +$4.46K ﹤0.01% 5092
2024
Q1 		$10K Buy
604
+324
+116% +$5.34K ﹤0.01% 5199
2023
Q4 		$4.47K Buy
280
+227
+428% +$14.1K ﹤0.01% 5350
2023
Q3 		$4.04K Sell
53
-235
-82% -$16K ﹤0.01% 4770
2023
Q2 		$18.9K Buy
+288
New +$23.2K ﹤0.01% 4969
2022
Q4 		– Sell
-750
Closed -$25K – 5998
2022
Q3 		$25K Sell
750
-38
-5% -$1.25K ﹤0.01% 4663
2022
Q2 		$21K Buy
788
+712
+937% +$16.6K ﹤0.01% 4986
2022
Q1 		$2K Sell
76
-187
-71% -$10.5K ﹤0.01% 6103
2021
Q4 		$22K Buy
263
+147
+127% +$10.8K ﹤0.01% 5363
2021
Q3 		$9K Buy
116
+86
+287% +$7.3K ﹤0.01% 5504
2021
Q2 		$3K Buy
+30
New +$3.35K ﹤0.01% 5939

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's OKUR Position: Q2 2026 in Review

Citigroup increased its OnKure Therapeutics (OKUR) stake by 1,218,900% in Q2 2026, buying an estimated $52.3K and bringing the position to 12,190 shares worth $55.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4940.

Citigroup first reported a position in OKUR in Q2 2021 and has held it in 19 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Citigroup held 12,190 shares of OnKure Therapeutics worth $55.6K as of Q2 2026.
  • Citigroup bought 12,189 OnKure Therapeutics shares in Q2 2026, an estimated $52.3K.
  • OnKure Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4940 holding.
  • Citigroup first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.